Scarica l'app Stockscreener
128.33
0.26%
0.33
Dopo l'orario di chiusura:
128.69
0.36
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$128.00
Aprire:
$129.41
Volume 24 ore:
9.44M
Relative Volume:
0.96
Capitalizzazione di mercato:
$316.95B
Reddito:
$65.51B
Utile/perdita netta:
$8.93B
Rapporto P/E:
36.12
EPS:
3.5532
Flusso di cassa netto:
$14.12B
1 W Prestazione:
-1.56%
1M Prestazione:
-0.95%
6M Prestazione:
+7.16%
1 anno Prestazione:
+58.84%
Intervallo 1D:
$127.56
$131.09
Intervallo di 1 settimana:
$126.22
$131.47
Portata 52W:
$77.58
$135.05
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
128.33 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,169.86 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.59 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
246.20 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
154.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-02-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-13 | Ripresa | Citigroup | Neutral |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Barclays Adjusts Merck & Co. Price Target to $150 From $140, Maintains Overweight Rating - marketscreener.com
Prediction: This Dividend ETF Will Thrive After 20 Years No Matter What the Market Does - The Motley Fool
Merck stock holds as 27 July 2026 article is built on filings and market context - Ad-hoc-news.de
Merck stock holds firm as oncology revenue supports valuation - Ad-hoc-news.de
Merck stock trades steadily as oncology revenue supports earnings outlook - Ad-hoc-news.de
Merck stock edges higher as Keytruda drives solid revenue growth - AD HOC NEWS
Merck & Co. stock holds after recent earnings and pipeline data - AD HOC NEWS
Merck & Co. Launches Early Access Program for Alimatravir - GuruFocus
Merck stock trades steadily as recent Keytruda momentum and solid oncology revenue frame valuation - AD HOC NEWS
Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries - CNBC TV18
Merck & Co., Inc. Revenue Breakdown – VIE:MRK - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Merck licenses experimental HIV pill to generic makers in 129 countries - Reuters
Merck signs licensing deals with companies including Viatris for new HIV pill - Seeking Alpha
Merck stock steadies as Keytruda drives Q1 2026 revenue growth - AD HOC NEWS
Merck stock holds recent gains as oncology and vaccines drive higher 2025 guidance - AD HOC NEWS
Merck's Once-Monthly HIV Prevention Pill Could Reach 129 Countries if Approved - Stock Titan
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development - Business Wire
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck stock trades steadily as Keytruda revenue supports earnings - Ad-hoc-news.de
Merck stock trades steadily as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds support after recent earnings and guidance - Ad-hoc-news.de
Return on assets % of Merck & Co., Inc. – BCS:MRK1 - TradingView
Operating margin % of Merck & Co., Inc. – BCS:MRKCL0 - TradingView
Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRK1 - TradingView
Net debt of Merck & Co., Inc. – BCS:MRK1 - TradingView
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRK0 - TradingView
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Commerzbank Aktiengesellschaft FI Decreases Stake in Merck & Co., Inc. $MRK - InsuranceNewsNet
Merck stock trades steadily as Keytruda and vaccine revenue underpin earnings - Ad-hoc-news.de
Merck stock trades steady as oncology and vaccines drive revenue growth - Ad-hoc-news.de
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $2,270,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck stock trades steadily as Keytruda growth underpins guidance - Ad-hoc-news.de
Merck & Co., Inc. (MRK) Stock Analysis: Navigating a 5.13% Upside Potential Amid Robust Growth - DirectorsTalk Interviews
Merck stock trades steady as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds firm as Keytruda drives revenue growth and late stage pipeline advances - ad-hoc-news.de
Merck stock holds steady as Keytruda drives revenue growth and investors watch oncology momentum - ad-hoc-news.de
Is Merck's Recent Restructuring a Confident Pivot or a Defensive Maneuver - Kavout | AI
Merck stock trades steady as Keytruda growth supports earnings outlook - ad-hoc-news.de
Merck stock trades steady as Keytruda growth underpins recent earnings - ad-hoc-news.de
Merck stock trades firm as Keytruda growth supports guidance - ad-hoc-news.de
Merck stock steadies as Keytruda drives double digit growth - ad-hoc-news.de
ETFs Investing in Merck & Co., Inc. Stocks - TradingView
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK) - Seeking Alpha
Merck stock trades near record territory as oncology and vaccines drive revenue growth - ad-hoc-news.de
MRK Stock Climbs As New Drugs And Targets Fuel Bull Case - StocksToTrade
New Cholesterol Pill, Earnings Growth Boost Merck Shares - FXEmpire
Merck stock edges higher as Keytruda drives double digit growth - ad-hoc-news.de
DUPONT CAPITAL MANAGEMENT Corp's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Merck Co Inc Azioni (MRK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Maraldo David R. | EVP & Pres. MMD |
May 02 '26 |
Option Exercise |
112.16 |
552 |
61,912 |
18,371 |
| Guindo Chirfi | EVP, Access, Policy & Comms |
Apr 29 '26 |
Option Exercise |
110.03 |
1,967 |
216,429 |
62,582 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD |
Apr 29 '26 |
Option Exercise |
110.03 |
2,597 |
285,748 |
16,477 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Apr 29 '26 |
Option Exercise |
110.03 |
2,518 |
277,056 |
162,778 |
| Williams David Michael | EVP,Chief Info&Digital Officer |
Apr 29 '26 |
Option Exercise |
110.03 |
1,377 |
151,511 |
32,395 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 29 '26 |
Option Exercise |
110.03 |
944 |
103,868 |
9,156 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 30 '26 |
Option Exercise |
110.95 |
464 |
51,481 |
9,296 |
| Li Dean Y | Executive VP & President, MRL |
Apr 29 '26 |
Option Exercise |
110.03 |
4,722 |
519,562 |
96,757 |
| Zachary Jennifer | EVP, General Counsel |
Apr 29 '26 |
Option Exercise |
110.03 |
2,951 |
324,699 |
72,351 |
| Larson Betty D | EVP, Chief HR Officer |
Apr 30 '26 |
Option Exercise |
110.95 |
11,350 |
1,259,282 |
18,917 |
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):